Disc Medicine (NASDAQ:IRON) Given Buy Rating at HC Wainwright

Disc Medicine (NASDAQ:IRON)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a note issued to investors on Tuesday, Benzinga reports. They currently have a $70.00 price target on the stock. HC Wainwright’s price objective points to a potential upside of 8.02% from the company’s previous close.

IRON has been the subject of a number of other reports. Wells Fargo & Company assumed coverage on shares of Disc Medicine in a research note on Thursday, August 22nd. They set an “overweight” rating and a $75.00 target price for the company. Scotiabank assumed coverage on shares of Disc Medicine in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $62.00 target price on the stock. Raymond James raised shares of Disc Medicine from an “outperform” rating to a “strong-buy” rating and lifted their price target for the company from $66.00 to $110.00 in a research note on Monday. Cantor Fitzgerald reissued an “overweight” rating and issued a $85.00 price objective on shares of Disc Medicine in a research note on Tuesday, October 15th. Finally, Morgan Stanley raised Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 target price for the company in a research report on Tuesday. Nine analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $80.20.

Disc Medicine Price Performance

Disc Medicine stock opened at $64.80 on Tuesday. Disc Medicine has a 1-year low of $25.60 and a 1-year high of $77.60. The company’s 50-day moving average is $49.06 and its 200 day moving average is $43.19.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($1.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.11) by $0.08. On average, equities research analysts anticipate that Disc Medicine will post -4.09 EPS for the current year.

Insider Transactions at Disc Medicine

In related news, Director William Richard White sold 7,136 shares of the stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $58.61, for a total transaction of $418,240.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 7,538 shares of company stock valued at $437,875 in the last 90 days. Insiders own 4.24% of the company’s stock.

Institutional Investors Weigh In On Disc Medicine

Large investors have recently modified their holdings of the business. Amalgamated Bank raised its position in shares of Disc Medicine by 76.9% in the 2nd quarter. Amalgamated Bank now owns 568 shares of the company’s stock valued at $26,000 after purchasing an additional 247 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Disc Medicine by 45.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company’s stock worth $54,000 after buying an additional 337 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Disc Medicine during the second quarter worth $129,000. SG Americas Securities LLC increased its position in shares of Disc Medicine by 44.2% in the 2nd quarter. SG Americas Securities LLC now owns 4,071 shares of the company’s stock valued at $183,000 after acquiring an additional 1,247 shares during the period. Finally, ProShare Advisors LLC purchased a new position in Disc Medicine in the 1st quarter worth $211,000. Hedge funds and other institutional investors own 83.70% of the company’s stock.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.